Trials / Completed
CompletedNCT04112498
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
A Phase 1, Multi-Tumor, Bioavailability Study of Relatlimab in Combination With Nivolumab
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | relatlimab | Specified dose on Specified days |
| DRUG | nivolumab | Specified dose on Specified days |
| DRUG | rHuPH20 | Specified dose on Specified days |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2023-02-27
- Completion
- 2023-02-27
- First posted
- 2019-10-02
- Last updated
- 2023-04-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04112498. Inclusion in this directory is not an endorsement.